nodes	percent_of_prediction	percent_of_DWPC	metapath
Glycopyrrolate—Hexylcaine—Diethylpropion—obesity	0.627	1	CrCrCtD
Glycopyrrolate—Dizziness—Phenylpropanolamine—obesity	0.00047	0.00214	CcSEcCtD
Glycopyrrolate—Abdominal distension—Bupropion—obesity	0.000465	0.00211	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Cimetidine—obesity	0.000464	0.00211	CcSEcCtD
Glycopyrrolate—Urinary tract infection—Sibutramine—obesity	0.000459	0.00209	CcSEcCtD
Glycopyrrolate—Cystitis noninfective—Topiramate—obesity	0.000458	0.00208	CcSEcCtD
Glycopyrrolate—Sinusitis—Orlistat—obesity	0.000458	0.00208	CcSEcCtD
Glycopyrrolate—Cystitis—Topiramate—obesity	0.000452	0.00206	CcSEcCtD
Glycopyrrolate—Sweating—Sibutramine—obesity	0.000452	0.00206	CcSEcCtD
Glycopyrrolate—Vomiting—Phenylpropanolamine—obesity	0.000452	0.00206	CcSEcCtD
Glycopyrrolate—Dizziness—Phentermine—obesity	0.00045	0.00205	CcSEcCtD
Glycopyrrolate—Rash—Phenylpropanolamine—obesity	0.000448	0.00204	CcSEcCtD
Glycopyrrolate—Dermatitis—Phenylpropanolamine—obesity	0.000448	0.00204	CcSEcCtD
Glycopyrrolate—Body temperature increased—Cimetidine—obesity	0.000445	0.00203	CcSEcCtD
Glycopyrrolate—Epistaxis—Sibutramine—obesity	0.000445	0.00203	CcSEcCtD
Glycopyrrolate—Sinusitis—Sibutramine—obesity	0.000443	0.00201	CcSEcCtD
Glycopyrrolate—Abdominal discomfort—Bupropion—obesity	0.000442	0.00201	CcSEcCtD
Glycopyrrolate—Photophobia—Topiramate—obesity	0.00044	0.002	CcSEcCtD
Glycopyrrolate—Vomiting—Phentermine—obesity	0.000433	0.00197	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Orlistat—obesity	0.000432	0.00197	CcSEcCtD
Glycopyrrolate—Dysuria—Bupropion—obesity	0.000432	0.00196	CcSEcCtD
Glycopyrrolate—Urethral disorder—Orlistat—obesity	0.000429	0.00195	CcSEcCtD
Glycopyrrolate—Rash—Phentermine—obesity	0.000429	0.00195	CcSEcCtD
Glycopyrrolate—Upper respiratory tract infection—Bupropion—obesity	0.000429	0.00195	CcSEcCtD
Glycopyrrolate—Dermatitis—Phentermine—obesity	0.000429	0.00195	CcSEcCtD
Glycopyrrolate—Headache—Phentermine—obesity	0.000426	0.00194	CcSEcCtD
Glycopyrrolate—Erectile dysfunction—Bupropion—obesity	0.000425	0.00193	CcSEcCtD
Glycopyrrolate—Rhinitis—Sibutramine—obesity	0.000425	0.00193	CcSEcCtD
Glycopyrrolate—Bladder pain—Topiramate—obesity	0.000424	0.00193	CcSEcCtD
Glycopyrrolate—Nausea—Phenylpropanolamine—obesity	0.000422	0.00192	CcSEcCtD
Glycopyrrolate—Hypoaesthesia—Sibutramine—obesity	0.000422	0.00192	CcSEcCtD
Glycopyrrolate—Hyperglycaemia—Bupropion—obesity	0.000416	0.00189	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Cimetidine—obesity	0.000415	0.00189	CcSEcCtD
Glycopyrrolate—Pneumonia—Bupropion—obesity	0.000414	0.00188	CcSEcCtD
Glycopyrrolate—Infestation NOS—Bupropion—obesity	0.000411	0.00187	CcSEcCtD
Glycopyrrolate—Infestation—Bupropion—obesity	0.000411	0.00187	CcSEcCtD
Glycopyrrolate—Nausea—Phentermine—obesity	0.000404	0.00184	CcSEcCtD
Glycopyrrolate—Asthenia—Cimetidine—obesity	0.000404	0.00184	CcSEcCtD
Glycopyrrolate—Urinary tract infection—Bupropion—obesity	0.0004	0.00182	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Orlistat—obesity	0.000395	0.0018	CcSEcCtD
Glycopyrrolate—Sweating—Bupropion—obesity	0.000394	0.00179	CcSEcCtD
Glycopyrrolate—Dizziness—Diethylpropion—obesity	0.000392	0.00178	CcSEcCtD
Glycopyrrolate—Epistaxis—Bupropion—obesity	0.000388	0.00177	CcSEcCtD
Glycopyrrolate—Sinusitis—Bupropion—obesity	0.000386	0.00176	CcSEcCtD
Glycopyrrolate—Gastroenteritis—Topiramate—obesity	0.000384	0.00175	CcSEcCtD
Glycopyrrolate—Mental disorder—Orlistat—obesity	0.000384	0.00175	CcSEcCtD
Glycopyrrolate—Malnutrition—Orlistat—obesity	0.000381	0.00173	CcSEcCtD
Glycopyrrolate—Vomiting—Diethylpropion—obesity	0.000376	0.00171	CcSEcCtD
Glycopyrrolate—Flatulence—Orlistat—obesity	0.000376	0.00171	CcSEcCtD
Glycopyrrolate—Nasal congestion—Topiramate—obesity	0.000373	0.0017	CcSEcCtD
Glycopyrrolate—Rash—Diethylpropion—obesity	0.000373	0.0017	CcSEcCtD
Glycopyrrolate—Dysgeusia—Orlistat—obesity	0.000373	0.0017	CcSEcCtD
Glycopyrrolate—Dermatitis—Diethylpropion—obesity	0.000373	0.0017	CcSEcCtD
Glycopyrrolate—Dizziness—Cimetidine—obesity	0.000373	0.0017	CcSEcCtD
Glycopyrrolate—Headache—Diethylpropion—obesity	0.000371	0.00169	CcSEcCtD
Glycopyrrolate—Rhinitis—Bupropion—obesity	0.00037	0.00168	CcSEcCtD
Glycopyrrolate—Malnutrition—Sibutramine—obesity	0.000369	0.00168	CcSEcCtD
Glycopyrrolate—Hypoaesthesia—Bupropion—obesity	0.000368	0.00167	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Bupropion—obesity	0.000365	0.00166	CcSEcCtD
Glycopyrrolate—Flatulence—Sibutramine—obesity	0.000363	0.00165	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Bupropion—obesity	0.000363	0.00165	CcSEcCtD
Glycopyrrolate—Urethral disorder—Bupropion—obesity	0.000362	0.00165	CcSEcCtD
Glycopyrrolate—Tension—Sibutramine—obesity	0.000362	0.00165	CcSEcCtD
Glycopyrrolate—Dysgeusia—Sibutramine—obesity	0.000361	0.00164	CcSEcCtD
Glycopyrrolate—Vision blurred—Orlistat—obesity	0.000359	0.00163	CcSEcCtD
Glycopyrrolate—Nervousness—Sibutramine—obesity	0.000358	0.00163	CcSEcCtD
Glycopyrrolate—Vomiting—Cimetidine—obesity	0.000358	0.00163	CcSEcCtD
Glycopyrrolate—Rash—Cimetidine—obesity	0.000355	0.00162	CcSEcCtD
Glycopyrrolate—Dermatitis—Cimetidine—obesity	0.000355	0.00161	CcSEcCtD
Glycopyrrolate—Headache—Cimetidine—obesity	0.000353	0.00161	CcSEcCtD
Glycopyrrolate—Nausea—Diethylpropion—obesity	0.000352	0.0016	CcSEcCtD
Glycopyrrolate—Vision blurred—Sibutramine—obesity	0.000348	0.00158	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Bupropion—obesity	0.000343	0.00156	CcSEcCtD
Glycopyrrolate—Flushing—Bupropion—obesity	0.000343	0.00156	CcSEcCtD
Glycopyrrolate—Pain in extremity—Topiramate—obesity	0.00034	0.00155	CcSEcCtD
Glycopyrrolate—Agitation—Sibutramine—obesity	0.000339	0.00154	CcSEcCtD
Glycopyrrolate—Palpitations—Orlistat—obesity	0.000337	0.00153	CcSEcCtD
Glycopyrrolate—Affect lability—Topiramate—obesity	0.000335	0.00152	CcSEcCtD
Glycopyrrolate—Nausea—Cimetidine—obesity	0.000335	0.00152	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Bupropion—obesity	0.000333	0.00151	CcSEcCtD
Glycopyrrolate—Convulsion—Orlistat—obesity	0.00033	0.0015	CcSEcCtD
Glycopyrrolate—Palpitations—Sibutramine—obesity	0.000326	0.00148	CcSEcCtD
Glycopyrrolate—Irritability—Topiramate—obesity	0.000325	0.00148	CcSEcCtD
Glycopyrrolate—Mental disorder—Bupropion—obesity	0.000324	0.00147	CcSEcCtD
Glycopyrrolate—Urinary retention—Topiramate—obesity	0.000323	0.00147	CcSEcCtD
Glycopyrrolate—Mood swings—Topiramate—obesity	0.000322	0.00147	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Orlistat—obesity	0.000322	0.00147	CcSEcCtD
Glycopyrrolate—Malnutrition—Bupropion—obesity	0.000322	0.00146	CcSEcCtD
Glycopyrrolate—Convulsion—Sibutramine—obesity	0.00032	0.00145	CcSEcCtD
Glycopyrrolate—Hypertension—Sibutramine—obesity	0.000318	0.00145	CcSEcCtD
Glycopyrrolate—Dry mouth—Orlistat—obesity	0.000317	0.00144	CcSEcCtD
Glycopyrrolate—Flatulence—Bupropion—obesity	0.000317	0.00144	CcSEcCtD
Glycopyrrolate—Dehydration—Topiramate—obesity	0.000316	0.00144	CcSEcCtD
Glycopyrrolate—Tension—Bupropion—obesity	0.000316	0.00144	CcSEcCtD
Glycopyrrolate—Dysgeusia—Bupropion—obesity	0.000315	0.00143	CcSEcCtD
Glycopyrrolate—Nervousness—Bupropion—obesity	0.000312	0.00142	CcSEcCtD
Glycopyrrolate—Oedema—Orlistat—obesity	0.000311	0.00142	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Orlistat—obesity	0.000311	0.00142	CcSEcCtD
Glycopyrrolate—Infection—Orlistat—obesity	0.000309	0.00141	CcSEcCtD
Glycopyrrolate—Dry mouth—Sibutramine—obesity	0.000307	0.0014	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Orlistat—obesity	0.000305	0.00139	CcSEcCtD
Glycopyrrolate—Nasopharyngitis—Topiramate—obesity	0.000304	0.00138	CcSEcCtD
Glycopyrrolate—Confusional state—Sibutramine—obesity	0.000304	0.00138	CcSEcCtD
Glycopyrrolate—Vision blurred—Bupropion—obesity	0.000303	0.00138	CcSEcCtD
Glycopyrrolate—Skin disorder—Orlistat—obesity	0.000302	0.00137	CcSEcCtD
Glycopyrrolate—Oedema—Sibutramine—obesity	0.000301	0.00137	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Sibutramine—obesity	0.000301	0.00137	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Orlistat—obesity	0.000301	0.00137	CcSEcCtD
Glycopyrrolate—Infection—Sibutramine—obesity	0.000299	0.00136	CcSEcCtD
Glycopyrrolate—Abdominal distension—Topiramate—obesity	0.000296	0.00135	CcSEcCtD
Glycopyrrolate—Agitation—Bupropion—obesity	0.000295	0.00134	CcSEcCtD
Glycopyrrolate—Tachycardia—Sibutramine—obesity	0.000294	0.00134	CcSEcCtD
Glycopyrrolate—Skin disorder—Sibutramine—obesity	0.000292	0.00133	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Sibutramine—obesity	0.000291	0.00132	CcSEcCtD
Glycopyrrolate—Palpitations—Bupropion—obesity	0.000284	0.00129	CcSEcCtD
Glycopyrrolate—Abdominal discomfort—Topiramate—obesity	0.000282	0.00128	CcSEcCtD
Glycopyrrolate—Insomnia—Orlistat—obesity	0.000281	0.00128	CcSEcCtD
Glycopyrrolate—Hypotension—Sibutramine—obesity	0.000281	0.00128	CcSEcCtD
Glycopyrrolate—Convulsion—Bupropion—obesity	0.000279	0.00127	CcSEcCtD
Glycopyrrolate—Hypertension—Bupropion—obesity	0.000278	0.00126	CcSEcCtD
Glycopyrrolate—Dysuria—Topiramate—obesity	0.000275	0.00125	CcSEcCtD
Glycopyrrolate—Dyspepsia—Orlistat—obesity	0.000274	0.00125	CcSEcCtD
Glycopyrrolate—Upper respiratory tract infection—Topiramate—obesity	0.000273	0.00124	CcSEcCtD
Glycopyrrolate—Insomnia—Sibutramine—obesity	0.000272	0.00124	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	0.000272	0.00124	CcSEcCtD
Glycopyrrolate—Erectile dysfunction—Topiramate—obesity	0.000271	0.00123	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Orlistat—obesity	0.000269	0.00122	CcSEcCtD
Glycopyrrolate—Fatigue—Orlistat—obesity	0.000268	0.00122	CcSEcCtD
Glycopyrrolate—Dry mouth—Bupropion—obesity	0.000268	0.00122	CcSEcCtD
Glycopyrrolate—Somnolence—Sibutramine—obesity	0.000268	0.00122	CcSEcCtD
Glycopyrrolate—Pain—Orlistat—obesity	0.000266	0.00121	CcSEcCtD
Glycopyrrolate—Hyperglycaemia—Topiramate—obesity	0.000265	0.00121	CcSEcCtD
Glycopyrrolate—Dyspepsia—Sibutramine—obesity	0.000265	0.00121	CcSEcCtD
Glycopyrrolate—Confusional state—Bupropion—obesity	0.000265	0.0012	CcSEcCtD
Glycopyrrolate—Pneumonia—Topiramate—obesity	0.000264	0.0012	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Bupropion—obesity	0.000262	0.00119	CcSEcCtD
Glycopyrrolate—Oedema—Bupropion—obesity	0.000262	0.00119	CcSEcCtD
Glycopyrrolate—Infestation—Topiramate—obesity	0.000262	0.00119	CcSEcCtD
Glycopyrrolate—Infestation NOS—Topiramate—obesity	0.000262	0.00119	CcSEcCtD
Glycopyrrolate—Infection—Bupropion—obesity	0.000261	0.00119	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Sibutramine—obesity	0.00026	0.00118	CcSEcCtD
Glycopyrrolate—Pain—Sibutramine—obesity	0.000257	0.00117	CcSEcCtD
Glycopyrrolate—Constipation—Sibutramine—obesity	0.000257	0.00117	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Bupropion—obesity	0.000257	0.00117	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Orlistat—obesity	0.000256	0.00117	CcSEcCtD
Glycopyrrolate—Tachycardia—Bupropion—obesity	0.000256	0.00117	CcSEcCtD
Glycopyrrolate—Skin disorder—Bupropion—obesity	0.000255	0.00116	CcSEcCtD
Glycopyrrolate—Urinary tract infection—Topiramate—obesity	0.000255	0.00116	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Orlistat—obesity	0.000254	0.00116	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Bupropion—obesity	0.000254	0.00115	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Sibutramine—obesity	0.000248	0.00113	CcSEcCtD
Glycopyrrolate—Epistaxis—Topiramate—obesity	0.000247	0.00113	CcSEcCtD
Glycopyrrolate—Urticaria—Orlistat—obesity	0.000247	0.00112	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Sibutramine—obesity	0.000246	0.00112	CcSEcCtD
Glycopyrrolate—Sinusitis—Topiramate—obesity	0.000246	0.00112	CcSEcCtD
Glycopyrrolate—Abdominal pain—Orlistat—obesity	0.000246	0.00112	CcSEcCtD
Glycopyrrolate—Body temperature increased—Orlistat—obesity	0.000246	0.00112	CcSEcCtD
Glycopyrrolate—Hypotension—Bupropion—obesity	0.000245	0.00112	CcSEcCtD
Glycopyrrolate—Urticaria—Sibutramine—obesity	0.000239	0.00109	CcSEcCtD
Glycopyrrolate—Body temperature increased—Sibutramine—obesity	0.000238	0.00108	CcSEcCtD
Glycopyrrolate—Abdominal pain—Sibutramine—obesity	0.000238	0.00108	CcSEcCtD
Glycopyrrolate—Insomnia—Bupropion—obesity	0.000237	0.00108	CcSEcCtD
Glycopyrrolate—Rhinitis—Topiramate—obesity	0.000236	0.00107	CcSEcCtD
Glycopyrrolate—Hypoaesthesia—Topiramate—obesity	0.000234	0.00107	CcSEcCtD
Glycopyrrolate—Somnolence—Bupropion—obesity	0.000233	0.00106	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Topiramate—obesity	0.000232	0.00106	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Topiramate—obesity	0.000231	0.00105	CcSEcCtD
Glycopyrrolate—Dyspepsia—Bupropion—obesity	0.000231	0.00105	CcSEcCtD
Glycopyrrolate—Urethral disorder—Topiramate—obesity	0.000231	0.00105	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Orlistat—obesity	0.000229	0.00104	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Bupropion—obesity	0.000227	0.00103	CcSEcCtD
Glycopyrrolate—Fatigue—Bupropion—obesity	0.000226	0.00103	CcSEcCtD
Glycopyrrolate—Pain—Bupropion—obesity	0.000224	0.00102	CcSEcCtD
Glycopyrrolate—Constipation—Bupropion—obesity	0.000224	0.00102	CcSEcCtD
Glycopyrrolate—Asthenia—Orlistat—obesity	0.000223	0.00102	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Sibutramine—obesity	0.000222	0.00101	CcSEcCtD
Glycopyrrolate—Pruritus—Orlistat—obesity	0.00022	0.001	CcSEcCtD
Glycopyrrolate—Flushing—Topiramate—obesity	0.000218	0.000994	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Topiramate—obesity	0.000218	0.000994	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Bupropion—obesity	0.000216	0.000984	CcSEcCtD
Glycopyrrolate—Asthenia—Sibutramine—obesity	0.000216	0.000983	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Bupropion—obesity	0.000215	0.000976	CcSEcCtD
Glycopyrrolate—Pruritus—Sibutramine—obesity	0.000213	0.000969	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Topiramate—obesity	0.000212	0.000965	CcSEcCtD
Glycopyrrolate—Urticaria—Bupropion—obesity	0.000208	0.000949	CcSEcCtD
Glycopyrrolate—Body temperature increased—Bupropion—obesity	0.000207	0.000944	CcSEcCtD
Glycopyrrolate—Abdominal pain—Bupropion—obesity	0.000207	0.000944	CcSEcCtD
Glycopyrrolate—Mental disorder—Topiramate—obesity	0.000206	0.000938	CcSEcCtD
Glycopyrrolate—Dizziness—Orlistat—obesity	0.000206	0.000936	CcSEcCtD
Glycopyrrolate—Malnutrition—Topiramate—obesity	0.000205	0.000932	CcSEcCtD
Glycopyrrolate—Erythema—Topiramate—obesity	0.000205	0.000932	CcSEcCtD
Glycopyrrolate—Flatulence—Topiramate—obesity	0.000202	0.000919	CcSEcCtD
Glycopyrrolate—Tension—Topiramate—obesity	0.000201	0.000915	CcSEcCtD
Glycopyrrolate—Dysgeusia—Topiramate—obesity	0.000201	0.000913	CcSEcCtD
Glycopyrrolate—Dizziness—Sibutramine—obesity	0.000199	0.000906	CcSEcCtD
Glycopyrrolate—Nervousness—Topiramate—obesity	0.000199	0.000905	CcSEcCtD
Glycopyrrolate—Vomiting—Orlistat—obesity	0.000198	0.0009	CcSEcCtD
Glycopyrrolate—Rash—Orlistat—obesity	0.000196	0.000892	CcSEcCtD
Glycopyrrolate—Dermatitis—Orlistat—obesity	0.000196	0.000892	CcSEcCtD
Glycopyrrolate—Headache—Orlistat—obesity	0.000195	0.000887	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Bupropion—obesity	0.000193	0.00088	CcSEcCtD
Glycopyrrolate—Vision blurred—Topiramate—obesity	0.000193	0.000878	CcSEcCtD
Glycopyrrolate—Vomiting—Sibutramine—obesity	0.000191	0.000871	CcSEcCtD
Glycopyrrolate—Rash—Sibutramine—obesity	0.00019	0.000864	CcSEcCtD
Glycopyrrolate—Dermatitis—Sibutramine—obesity	0.00019	0.000863	CcSEcCtD
Glycopyrrolate—Headache—Sibutramine—obesity	0.000189	0.000858	CcSEcCtD
Glycopyrrolate—Asthenia—Bupropion—obesity	0.000188	0.000857	CcSEcCtD
Glycopyrrolate—Agitation—Topiramate—obesity	0.000188	0.000857	CcSEcCtD
Glycopyrrolate—Pruritus—Bupropion—obesity	0.000186	0.000845	CcSEcCtD
Glycopyrrolate—Nausea—Orlistat—obesity	0.000185	0.000841	CcSEcCtD
Glycopyrrolate—Palpitations—Topiramate—obesity	0.000181	0.000824	CcSEcCtD
Glycopyrrolate—Nausea—Sibutramine—obesity	0.000179	0.000814	CcSEcCtD
Glycopyrrolate—Convulsion—Topiramate—obesity	0.000177	0.000808	CcSEcCtD
Glycopyrrolate—Hypertension—Topiramate—obesity	0.000177	0.000805	CcSEcCtD
Glycopyrrolate—Dizziness—Bupropion—obesity	0.000174	0.00079	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	0.000173	0.000788	CcSEcCtD
Glycopyrrolate—Dry mouth—Topiramate—obesity	0.000171	0.000776	CcSEcCtD
Glycopyrrolate—Confusional state—Topiramate—obesity	0.000169	0.000767	CcSEcCtD
Glycopyrrolate—Oedema—Topiramate—obesity	0.000167	0.000761	CcSEcCtD
Glycopyrrolate—Vomiting—Bupropion—obesity	0.000167	0.000759	CcSEcCtD
Glycopyrrolate—Infection—Topiramate—obesity	0.000166	0.000756	CcSEcCtD
Glycopyrrolate—Rash—Bupropion—obesity	0.000165	0.000753	CcSEcCtD
Glycopyrrolate—Dermatitis—Bupropion—obesity	0.000165	0.000752	CcSEcCtD
Glycopyrrolate—Headache—Bupropion—obesity	0.000164	0.000748	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Topiramate—obesity	0.000164	0.000746	CcSEcCtD
Glycopyrrolate—Tachycardia—Topiramate—obesity	0.000163	0.000742	CcSEcCtD
Glycopyrrolate—Skin disorder—Topiramate—obesity	0.000162	0.000739	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Topiramate—obesity	0.000162	0.000735	CcSEcCtD
Glycopyrrolate—Hypotension—Topiramate—obesity	0.000156	0.000711	CcSEcCtD
Glycopyrrolate—Nausea—Bupropion—obesity	0.000156	0.000709	CcSEcCtD
Glycopyrrolate—Insomnia—Topiramate—obesity	0.000151	0.000688	CcSEcCtD
Glycopyrrolate—Somnolence—Topiramate—obesity	0.000149	0.000676	CcSEcCtD
Glycopyrrolate—Dyspepsia—Topiramate—obesity	0.000147	0.00067	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Topiramate—obesity	0.000144	0.000657	CcSEcCtD
Glycopyrrolate—Fatigue—Topiramate—obesity	0.000144	0.000656	CcSEcCtD
Glycopyrrolate—Pain—Topiramate—obesity	0.000143	0.000651	CcSEcCtD
Glycopyrrolate—Constipation—Topiramate—obesity	0.000143	0.000651	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Topiramate—obesity	0.000138	0.000627	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Topiramate—obesity	0.000137	0.000622	CcSEcCtD
Glycopyrrolate—Urticaria—Topiramate—obesity	0.000133	0.000604	CcSEcCtD
Glycopyrrolate—Body temperature increased—Topiramate—obesity	0.000132	0.000601	CcSEcCtD
Glycopyrrolate—Abdominal pain—Topiramate—obesity	0.000132	0.000601	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Topiramate—obesity	0.000123	0.00056	CcSEcCtD
Glycopyrrolate—Asthenia—Topiramate—obesity	0.00012	0.000546	CcSEcCtD
Glycopyrrolate—Pruritus—Topiramate—obesity	0.000118	0.000538	CcSEcCtD
Glycopyrrolate—Dizziness—Topiramate—obesity	0.000111	0.000503	CcSEcCtD
Glycopyrrolate—Vomiting—Topiramate—obesity	0.000106	0.000484	CcSEcCtD
Glycopyrrolate—Rash—Topiramate—obesity	0.000105	0.00048	CcSEcCtD
Glycopyrrolate—Dermatitis—Topiramate—obesity	0.000105	0.000479	CcSEcCtD
Glycopyrrolate—Headache—Topiramate—obesity	0.000105	0.000477	CcSEcCtD
Glycopyrrolate—Nausea—Topiramate—obesity	9.93e-05	0.000452	CcSEcCtD
Glycopyrrolate—CHRM5—Signaling Pathways—ESR1—obesity	9.67e-06	6.3e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—SOCS1—obesity	9.67e-06	6.3e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—CD36—obesity	9.64e-06	6.28e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—SOCS1—obesity	9.64e-06	6.28e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—PIK3CD—obesity	9.58e-06	6.24e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—F2—obesity	9.55e-06	6.22e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—PRKCB—obesity	9.55e-06	6.22e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—PIK3CD—obesity	9.55e-06	6.22e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—SOCS3—obesity	9.55e-06	6.22e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—PIK3CG—obesity	9.55e-06	6.22e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—SOCS1—obesity	9.54e-06	6.22e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—SOCS3—obesity	9.52e-06	6.2e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—PIK3CD—obesity	9.46e-06	6.16e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—BAD—obesity	9.44e-06	6.15e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—IRS1—obesity	9.44e-06	6.15e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—SOCS3—obesity	9.43e-06	6.14e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—GNB3—obesity	9.35e-06	6.09e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—GNB3—obesity	9.32e-06	6.07e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—GNB3—obesity	9.23e-06	6.01e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—TYK2—obesity	9.22e-06	6e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—GPCR downstream signaling—PIK3CB—obesity	9.2e-06	5.99e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—TYK2—obesity	9.19e-06	5.98e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—IGF2—obesity	9.18e-06	5.98e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—GPCR downstream signaling—PIK3CB—obesity	9.17e-06	5.97e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—IGF2—obesity	9.15e-06	5.96e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—PIK3CG—obesity	9.14e-06	5.96e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—RHOA—obesity	9.14e-06	5.95e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—MTHFR—obesity	9.13e-06	5.95e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—RHOA—obesity	9.11e-06	5.93e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—GNAS—obesity	9.1e-06	5.93e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—TYK2—obesity	9.1e-06	5.93e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—POMC—obesity	9.09e-06	5.92e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—GPCR downstream signaling—PIK3CB—obesity	9.08e-06	5.91e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—GNAS—obesity	9.07e-06	5.91e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—IGF2—obesity	9.06e-06	5.9e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—PIK3R1—obesity	9.05e-06	5.89e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—INS—obesity	9.04e-06	5.89e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—IRS1—obesity	9.04e-06	5.89e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—RHOA—obesity	9.02e-06	5.88e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—PIK3R1—obesity	9.02e-06	5.87e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—GNAS—obesity	8.98e-06	5.85e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PPARA—obesity	8.96e-06	5.84e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—PIK3R1—obesity	8.93e-06	5.82e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—APOB—obesity	8.91e-06	5.81e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—CCL2—obesity	8.89e-06	5.79e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—APOB—obesity	8.88e-06	5.79e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—APOB—obesity	8.8e-06	5.73e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—IGF1—obesity	8.74e-06	5.69e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—AKT2—obesity	8.74e-06	5.69e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—POMC—obesity	8.7e-06	5.67e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CCL5—obesity	8.7e-06	5.67e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—AGT—obesity	8.68e-06	5.65e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CCL5—obesity	8.68e-06	5.65e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—INS—obesity	8.65e-06	5.64e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CCL5—obesity	8.59e-06	5.6e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—CCL2—obesity	8.52e-06	5.55e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—LPL—obesity	8.51e-06	5.54e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—APOE—obesity	8.5e-06	5.54e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—LPL—obesity	8.48e-06	5.53e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—FOXO1—obesity	8.45e-06	5.5e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—RPS6KB1—obesity	8.43e-06	5.49e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—CAV1—obesity	8.43e-06	5.49e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—FOXO1—obesity	8.42e-06	5.49e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—RPS6KB1—obesity	8.41e-06	5.48e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—APOA1—obesity	8.41e-06	5.48e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—LPL—obesity	8.4e-06	5.47e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—PIK3CD—obesity	8.39e-06	5.47e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—IGF1—obesity	8.37e-06	5.45e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—AKT2—obesity	8.37e-06	5.45e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—PIK3CB—obesity	8.35e-06	5.44e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—FOXO1—obesity	8.34e-06	5.43e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—RPS6KB1—obesity	8.33e-06	5.42e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—PIK3CB—obesity	8.32e-06	5.42e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—GPCR downstream signaling—PIK3CA—obesity	8.31e-06	5.42e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—SERPINE1—obesity	8.3e-06	5.41e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—PIK3CB—obesity	8.24e-06	5.37e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—TYK2—obesity	8.07e-06	5.26e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—PIK3CD—obesity	8.04e-06	5.24e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—RHOA—obesity	8.01e-06	5.22e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—GPCR downstream signaling—PIK3CA—obesity	7.96e-06	5.19e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—SERPINE1—obesity	7.95e-06	5.18e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—PIK3R1—obesity	7.93e-06	5.16e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—NOS3—obesity	7.93e-06	5.16e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—PRKCD—obesity	7.84e-06	5.11e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—PRKCD—obesity	7.82e-06	5.09e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—PRKCD—obesity	7.74e-06	5.04e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—TYK2—obesity	7.73e-06	5.04e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PIK3CG—obesity	7.67e-06	5e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—HTR2A—obesity	7.67e-06	5e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—RHOA—obesity	7.67e-06	5e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—C3—obesity	7.66e-06	4.99e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—HTR2A—obesity	7.65e-06	4.98e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—C3—obesity	7.64e-06	4.97e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—PIK3R1—obesity	7.59e-06	4.94e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—NOS3—obesity	7.59e-06	4.94e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—HTR2A—obesity	7.57e-06	4.93e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—C3—obesity	7.56e-06	4.93e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling by GPCR—PIK3CA—obesity	7.55e-06	4.92e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PPARG—obesity	7.41e-06	4.82e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—MTOR—obesity	7.32e-06	4.77e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—PIK3CB—obesity	7.32e-06	4.77e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—POMC—obesity	7.31e-06	4.76e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—IRS2—obesity	7.29e-06	4.75e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—AGT—obesity	7.28e-06	4.74e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—IRS2—obesity	7.27e-06	4.73e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—INS—obesity	7.26e-06	4.73e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—AGT—obesity	7.26e-06	4.73e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling by GPCR—PIK3CA—obesity	7.23e-06	4.71e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—IRS2—obesity	7.2e-06	4.69e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—AGT—obesity	7.19e-06	4.68e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—APOE—obesity	7.13e-06	4.65e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—LEP—obesity	7.13e-06	4.65e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—LEP—obesity	7.11e-06	4.63e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—APOE—obesity	7.11e-06	4.63e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CAV1—obesity	7.07e-06	4.6e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—APOA1—obesity	7.05e-06	4.59e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CAV1—obesity	7.05e-06	4.59e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—LEP—obesity	7.04e-06	4.59e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—APOE—obesity	7.04e-06	4.59e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—APOA1—obesity	7.03e-06	4.58e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—MTOR—obesity	7.01e-06	4.56e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—PIK3CB—obesity	7.01e-06	4.56e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CAV1—obesity	6.98e-06	4.54e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—APOA1—obesity	6.96e-06	4.53e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—ESR1—obesity	6.81e-06	4.44e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—GPCR downstream signaling—AKT1—obesity	6.79e-06	4.42e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—ESR1—obesity	6.79e-06	4.42e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PIK3CD—obesity	6.75e-06	4.39e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—F2—obesity	6.73e-06	4.38e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—PRKCB—obesity	6.73e-06	4.38e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—ESR1—obesity	6.72e-06	4.38e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—PRKCB—obesity	6.71e-06	4.37e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—F2—obesity	6.71e-06	4.37e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling by GPCR—IL6—obesity	6.69e-06	4.35e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—ALB—obesity	6.66e-06	4.34e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—BAD—obesity	6.65e-06	4.33e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—PRKCB—obesity	6.64e-06	4.33e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—F2—obesity	6.64e-06	4.33e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—BAD—obesity	6.63e-06	4.32e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—BAD—obesity	6.56e-06	4.27e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—GPCR downstream signaling—AKT1—obesity	6.5e-06	4.24e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—PIK3CG—obesity	6.44e-06	4.19e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—PIK3CG—obesity	6.42e-06	4.18e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling by GPCR—IL6—obesity	6.4e-06	4.17e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PIK3R1—obesity	6.37e-06	4.15e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—NOS3—obesity	6.37e-06	4.15e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—IRS1—obesity	6.36e-06	4.14e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—MMP9—obesity	6.36e-06	4.14e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—PIK3CG—obesity	6.35e-06	4.14e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—IRS1—obesity	6.34e-06	4.13e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—IRS1—obesity	6.28e-06	4.09e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—MAPK8—obesity	6.18e-06	4.03e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling by GPCR—AKT1—obesity	6.17e-06	4.02e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—POMC—obesity	6.13e-06	3.99e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—POMC—obesity	6.11e-06	3.98e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—INS—obesity	6.09e-06	3.97e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—MMP9—obesity	6.09e-06	3.97e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—INS—obesity	6.07e-06	3.96e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—POMC—obesity	6.05e-06	3.94e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—INS—obesity	6.02e-06	3.92e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—CCL2—obesity	6e-06	3.91e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—CCL2—obesity	5.98e-06	3.89e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—MAPK8—obesity	5.92e-06	3.86e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—CCL2—obesity	5.92e-06	3.86e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling by GPCR—AKT1—obesity	5.91e-06	3.85e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—IGF1—obesity	5.89e-06	3.84e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—AKT2—obesity	5.89e-06	3.84e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PIK3CB—obesity	5.88e-06	3.83e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—IGF1—obesity	5.88e-06	3.83e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—AKT2—obesity	5.87e-06	3.82e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PTGS2—obesity	5.83e-06	3.8e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—IGF1—obesity	5.82e-06	3.79e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—AKT2—obesity	5.81e-06	3.79e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—PIK3CD—obesity	5.66e-06	3.69e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—STAT3—obesity	5.65e-06	3.68e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—PIK3CD—obesity	5.64e-06	3.67e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—GPCR downstream signaling—PIK3CA—obesity	5.61e-06	3.65e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—SERPINE1—obesity	5.6e-06	3.65e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—GPCR downstream signaling—PIK3CA—obesity	5.59e-06	3.64e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—PIK3CD—obesity	5.59e-06	3.64e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—SERPINE1—obesity	5.58e-06	3.63e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—GPCR downstream signaling—PIK3CA—obesity	5.53e-06	3.6e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—SERPINE1—obesity	5.53e-06	3.6e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—TYK2—obesity	5.44e-06	3.55e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—TYK2—obesity	5.43e-06	3.53e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—STAT3—obesity	5.41e-06	3.53e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—RHOA—obesity	5.4e-06	3.52e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—RHOA—obesity	5.38e-06	3.51e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—TYK2—obesity	5.37e-06	3.5e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—NOS3—obesity	5.34e-06	3.48e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—PIK3R1—obesity	5.34e-06	3.48e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—RHOA—obesity	5.33e-06	3.47e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—PIK3R1—obesity	5.33e-06	3.47e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—NOS3—obesity	5.33e-06	3.47e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—PIK3R1—obesity	5.28e-06	3.44e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—NOS3—obesity	5.28e-06	3.44e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—MYC—obesity	5.25e-06	3.42e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—TGFB1—obesity	5.24e-06	3.41e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—PIK3CA—obesity	5.09e-06	3.32e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—PIK3CA—obesity	5.07e-06	3.31e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—MYC—obesity	5.03e-06	3.28e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—PIK3CA—obesity	5.03e-06	3.27e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—TGFB1—obesity	5.02e-06	3.27e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—MTOR—obesity	4.93e-06	3.21e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—PIK3CB—obesity	4.93e-06	3.21e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—MTOR—obesity	4.92e-06	3.2e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—PIK3CB—obesity	4.92e-06	3.2e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—MTOR—obesity	4.87e-06	3.17e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—PIK3CB—obesity	4.87e-06	3.17e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—GPCR downstream signaling—AKT1—obesity	4.58e-06	2.98e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—GPCR downstream signaling—AKT1—obesity	4.56e-06	2.97e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—GPCR downstream signaling—AKT1—obesity	4.52e-06	2.94e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—IL6—obesity	4.51e-06	2.94e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—IL6—obesity	4.49e-06	2.93e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—PIK3CA—obesity	4.46e-06	2.9e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—IL6—obesity	4.45e-06	2.9e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—MMP9—obesity	4.29e-06	2.79e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—MMP9—obesity	4.27e-06	2.78e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—PIK3CA—obesity	4.27e-06	2.78e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—MMP9—obesity	4.23e-06	2.76e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—MAPK8—obesity	4.17e-06	2.72e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling by GPCR—AKT1—obesity	4.16e-06	2.71e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—MAPK8—obesity	4.16e-06	2.71e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling by GPCR—AKT1—obesity	4.15e-06	2.7e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—MAPK8—obesity	4.12e-06	2.68e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling by GPCR—AKT1—obesity	4.11e-06	2.67e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—IL6—obesity	3.95e-06	2.57e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—STAT3—obesity	3.81e-06	2.48e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—STAT3—obesity	3.8e-06	2.48e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—IL6—obesity	3.78e-06	2.46e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—STAT3—obesity	3.76e-06	2.45e-05	CbGpPWpGaD
Glycopyrrolate—CHRM4—Signaling Pathways—AKT1—obesity	3.64e-06	2.37e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—PIK3CA—obesity	3.58e-06	2.33e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—MYC—obesity	3.54e-06	2.31e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—TGFB1—obesity	3.53e-06	2.3e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—MYC—obesity	3.53e-06	2.3e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—TGFB1—obesity	3.52e-06	2.29e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—MYC—obesity	3.5e-06	2.28e-05	CbGpPWpGaD
Glycopyrrolate—CHRM5—Signaling Pathways—AKT1—obesity	3.49e-06	2.27e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—TGFB1—obesity	3.49e-06	2.27e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—PIK3CA—obesity	3.01e-06	1.96e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—PIK3CA—obesity	3e-06	1.95e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—PIK3CA—obesity	2.97e-06	1.93e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Metabolism—AKT1—obesity	2.93e-06	1.91e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—IL6—obesity	2.66e-06	1.73e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—IL6—obesity	2.65e-06	1.73e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—IL6—obesity	2.63e-06	1.71e-05	CbGpPWpGaD
Glycopyrrolate—CHRM1—Signaling Pathways—AKT1—obesity	2.46e-06	1.6e-05	CbGpPWpGaD
Glycopyrrolate—CHRM3—Signaling Pathways—AKT1—obesity	2.45e-06	1.59e-05	CbGpPWpGaD
Glycopyrrolate—CHRM2—Signaling Pathways—AKT1—obesity	2.42e-06	1.58e-05	CbGpPWpGaD
